Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VB10 NEO

Next Previous
Drug Profile

VB10 NEO

Alternative Names: VB-10-NEO; VB10.NEO

Latest Information Update: 07 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccibody
  • Developer Nektar Therapeutics; Nykode Therapeutics
  • Class Antineoplastics; Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Phase I Solid tumours

Most Recent Events

  • 30 Apr 2023 Updated adverse event and immunogenicity data from a phase I/IIa trial in Solid tumours presented at the114th Annual Meeting of the American Association for Cancer Research
  • 30 Jan 2023 Vaccibody completes the DIRECT-01 phase-I/II trial in Urogenital cancer, Renal cell carcinoma and Non-small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease) in Germany (IM) (EudraCT2017-002474-39) (NCT03548467)
  • 26 Oct 2022 Preliminary positive adverse events and immunogenicity data from a phase I/IIa DIRECT-01 trial in locally advanced or metastatic melanoma, non-small cell lung cancer, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck released by Nykode Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top